Repository logo
 

Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters.

Published version
Peer-reviewed

Change log

Authors

Javierre, Biola M 
Burren, Oliver S 
Wilder, Steven P 
Kreuzhuber, Roman 
Hill, Steven M 

Abstract

Long-range interactions between regulatory elements and gene promoters play key roles in transcriptional regulation. The vast majority of interactions are uncharted, constituting a major missing link in understanding genome control. Here, we use promoter capture Hi-C to identify interacting regions of 31,253 promoters in 17 human primary hematopoietic cell types. We show that promoter interactions are highly cell type specific and enriched for links between active promoters and epigenetically marked enhancers. Promoter interactomes reflect lineage relationships of the hematopoietic tree, consistent with dynamic remodeling of nuclear architecture during differentiation. Interacting regions are enriched in genetic variants linked with altered expression of genes they contact, highlighting their functional role. We exploit this rich resource to connect non-coding disease variants to putative target promoters, prioritizing thousands of disease-candidate genes and implicating disease pathways. Our results demonstrate the power of primary cell promoter interactomes to reveal insights into genomic regulatory mechanisms underlying common diseases.

Description

Keywords

chromosome conformation, disease gene prioritization, gene regulation, non-coding genetic variation, promoter capture Hi-C, Blood Cells, Cell Lineage, Cell Separation, Chromatin, Disease, Enhancer Elements, Genetic, Epigenomics, Genetic Predisposition to Disease, Genome-Wide Association Study, Hematopoiesis, Humans, Polymorphism, Single Nucleotide, Promoter Regions, Genetic, Quantitative Trait Loci

Journal Title

Cell

Conference Name

Journal ISSN

0092-8674
1097-4172

Volume Title

167

Publisher

Elsevier BV
Sponsorship
Wellcome Trust (107881/Z/15/Z)
MRC (unknown)
Wellcome Trust (089989/Z/09/Z)
Wellcome Trust (100140/Z/12/Z)
European Commission (241447)
European Commission (282510)
Wellcome Trust (107212/Z/15/Z)
Wellcome Trust (091157/Z/10/B)
British Heart Foundation (None)
British Heart Foundation (None)
Medical Research Council (MC_UU_00002/4)
CCF (None)
This work was supported by the following grants: UK Medical Research Council (MR/L007150/1, MC_UP_1302/1, MC_UP_1302/3, MC_UP_1302/5), UK Biotechnology and Biological Sciences Research Council (BB/J004480/1), ERC (DEVOCHROMO advanced grant), JDRF (9-2011-253, 5-SRA-2015-130), Wellcome Trust (089989, 091157, 095908, 100140, 107212, 107881), European Union 7th Framework Programme (FP7/2007-2013, grant agreements 241447 [NAIMIT] and 282510 [BLUEPRINT]), NHS Blood and Transplant, NIHR (PG-0310-1002), and BHF (RG/09/12/28096). K.D. is funded by NHS Health Education England. M.F. is supported by the BHF Cambridge Centre of Excellence (RE/13/6/30180). S.P.W., M.K., D.R.Z., and O.S. are funded by the European Molecular Biology Laboratory.